EFFECT OF NANOCURCUMIN ON CISPLATIN-INDUCED ACUTE KIDNEY INJURY: A FOCUS ON NRF2 AND KEAP1

BASHAR ADI WAHYU PANDHITA, VIVIAN SOETIKNO*, MELVA LOUISA
Department of Pharmacology and Therapeutics, Faculty of Medicine, Universitas Indonesia, Jakarta, 10430, Indonesia.
Email: vivian_09st@yahoo.com

Received: 18 July 2018, Revised and Accepted: 15 November 2018

INTRODUCTION

Cisplatin (CDPP) is a platinum-based drug for the treatment of cancer. Despite its effectiveness, CDPP induces acute kidney injury (AKI). A quarter to one-third of patients receiving CDPP develop signs of acute nephrotoxicity such as reduced glomerular filtration and decreased serum magnesium and potassium [1].

Uptake of CDPP by the kidney is very high, which can result in nephrotoxicity. The known mechanism of CDPP-induced nephrotoxicity is through activation of the tubular intracellular signaling pathway, which includes the activation of apoptotic mechanisms and increased production of oxygen radicals [2]. In addition, CDPP can react with glutathione and inhibit enzymes involved in the antioxidant system such as glutathione peroxidase, glutathione S-transferase, and superoxide dismutase. Moreover, CDPP can bind to cytochrome P450 in microsomes, thereby increasing the production of radical oxygen species. All of these mechanisms lead to oxidative stress, which is characterized by a shift in intracellular oxidative balance and activation of the apoptotic pathway, resulting in cell death [3,4].

The Nrf2 gene plays a role in the antioxidant system and has been shown to be protective against various diseases including AKI [5]. In its normal state, Nrf2 is suppressed by association with Keap1, resulting in the intracellular pooling of inactive Nrf2. Dissociation of Keap1 activates Nrf2, which functions to protect against oxidative stress and protease damage [6].

Curcumin is an active compound of the turmeric plant (Curcuma longa) rhizome that has been shown to ameliorate organ damage due to oxidative stress by increasing Nrf2 activation and reducing the cytoplasmic abundance of Keap1, thus allowing Nrf2 activation [7-9].

METHODS

Animals
A total of 23 male Sprague-Dawley rats were obtained from the Agency for Health Research and Development (Jakarta, Indonesia) and housed at 22±2°C and relative humidity of 65±10% with ad libitum access to standard rat chow and water. All experimental protocols were approved by the Animal Ethics Committee of Universitas Indonesia.

Chemicals
Nanocurcumin (NC) and curcumin were purchased from Plamed Green Science Group (Xi’an, China). Molecular analysis showed that the average size of NC was 240.7±53.5 nm, while that of curcumin was 331.7±91.0 nm. Curcumin and NC were suspended in 0.5% carboxymethylcellulose (CMC). CDPP was obtained from Sigma-Aldrich (St. Louis, MO, USA) and dissolved in normal saline (0.9% NaCl).

All reagents for reverse transcription polymerase chain reaction (RT-PCR) analysis were purchased from Genetika Science (Jakarta, Indonesia), while disposable materials (gloves, pipette tip, etc.) were a generous gift from the Department of Pharmacology and Therapeutics, Faculty of Medicine, University of Indonesia.

Experimental treatment
The rats were acclimatized for 7 days with ad libitum access to food and water, and administered 0.5% Na-CMC. Before experimentation, the rats were randomly allocated to one of five groups: Control (four rats), CDPP (four rats), CDPP+100 mg curcumin (CDPP+Cur) (five rats), CDPP+50 mg NC (CDPP+50 NC) (five rats), and CDPP+100 mg NC (CDPP+100 NC) (five rats). Rats in the control group were given 0.5% CMC-Na orally for 9 days, with a single intraperitoneal injection of 0.9% normal saline on day 7. Rats in the CDPP group were given 0.5% CMC-Na once daily p.o. (orally) for 9 days, with a single intraperitoneal injection of CDPP (7 mg/kg BW) on day 7. Rats in the CDPP+Cur group were given curcumin (100 mg/kg BW) once daily p.o. for 9 days, with a single intraperitoneal injection of CDPP (7 mg/kg BW) on day 7. Rats in the CDPP+50 NC group were given NC (50 mg/kg BW) once daily p.o. for 9 days, with a single intraperitoneal injection of CDPP (7 mg/kg BW) on day 7. Rats in the CDPP+100 NC group were given NC (100 mg/kg BW) once daily p.o. for 9 days, with a single intraperitoneal injection of CDPP (7 mg/kg BW) on day 7.

RESULTS
There were no statistically significant differences in the RT-PCR results among the groups (p>0.05). However, Keap1 expression was upregulated in rats treated with 100 mg of NC, which may have been caused by increased Nrf2 activation and activation of a negative feedback loop, which upregulated transcription of Keap1.

Conclusion:
NC increased Keap1 levels, but not significantly.

Keywords: Cisplatin, Keap1, Nanocurcumin, Nephrotoxicity, Nrf2.

© 2018 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/) DOI: http://dx.doi.org/10.22159/ijap.2018.v10s1.32
injection of CDPP (7 mg/kg BW) on day 7. After treatment, the rats were anesthetized and sacrificed by decapitation. Whole kidneys were collected and stored at −80°C for further analysis.

**Kidney homogenization**
The kidneys were homogenized in ice-cold saline (0.9% NaCl) using a rotor-stator and then centrifuged at 3000 g for 10 min at 4°C. The supernatant was then stored at −80°C for RT-PCR analysis.

**Nrf2 and Keap1 gene expression analysis**
cDNA was synthesized using a cDNA synthesis kit (Roche Life Science, Penzberg, Germany). A Nanodrop 2000 spectrophotometer (NanoDrop Technologies, LLC, Wilmington, DE, USA) was used to assess cDNA purity and concentration. RT-PCR analysis of Nrf2 and Keap1 was performed.

After RT-PCR, gene expression was examined by electrophoresis (Bio-Rad Laboratories, Hercules, CA, USA). Samples were mixed with loading dye (SYBR Green) and then electrophoresed for 10 min at 220 V in a 2% Tris-acetate-ethylenediaminetetraacetic acid buffer. Results were interpreted using the Gel Doc™ EZ Gel Documentation System (Bio-Rad Laboratories).

**RESULTS**
The RT-PCR results of the Nrf2 gene showed that the average relative expression levels in the CDPP, CDPP+Curcumin, CDPP+50 NC, and CDPP+100 NC groups were 1.40, 1.08, 0.85, and 0.80, respectively (Fig. 1, Table 1). However, since the data distribution was not normal, the median values were used for analysis.

The average relative Keap1 gene expression levels of the CDPP, CDPP+Curcumin, CDPP+50 NC, and CDPP+100 NC groups were 3.85, 3.80, 2.34, and 2.92, respectively (Fig. 2, Table 1).

The statistical analysis results showed that there was no significant difference in Nrf2 and Keap1 expression levels among the groups (p>0.05).

After RT-PCR analysis, electrophoresis was performed, but the results were inconclusive due to the very small differences between the genes. However, several variations within groups were observed (Figs. 3 and 4).

**DISCUSSION**
A previous study by Waly et al. reported an association between curcumin administration and CDPP-induced kidney cell damage, through the activation of antioxidant enzymes [10].

An animal study also found that curcumin conveyed a nephroprotective effect against CDPP-induced nephrotoxicity. However, that study focused on antioxidant enzymes rather than gene expression profiles [11].

Our research suggests that there is no association between NC administration and Keap1 and Nrf2 gene expression. A possible explanation for this discrepancy is the failure of this study to differentiate between nuclear and cytoplasmic levels, as Nrf2 might be translocated to the nucleus.

A previous study reported that curcumin administration significantly increased the level of internalized Nrf2 [12]. However, no study has yet investigated the effect of curcumin on Nrf2 at the transcript level. In addition, studies that described the effect of curcumin on Nrf2 related the findings to chronic kidney failure [6,12]. In the present study, it...
is possible that Nrf2 levels did not significantly increase because the intracellular pool of Nrf2 had not yet been depleted.

A literature search retrieved only one study addressing the effect of curcumin on Keap1 expression, which found that curcumin can relieve Keap1 inhibition of Nrf2 [13]. However, in the present study, curcumin had no effect on Keap1 at the transcript level.

The results of this study showed that Keap1 transcription was upregulated in rats treated with 100 mg of NC. Thus, it is possible that NC increased the level of unbound Nrf2, which then activated a negative feedback mechanism that caused the cell to increase Keap1 transcription.

NC tended to upregulate, but not significantly, Keap1 gene expression, suggesting that the bioavailability of NC is greater than that of curcumin. In fact, it has been reported that the bioavailability of NC is 5 times greater than that of curcumin [14].

There were several limitations to this study. First, the data were not normally distributed, thus the possibility of result bias was high. Second, since two rats were excluded, the number of rats varied among the groups, which may have affected the results.

CONCLUSION
NC was found to upregulate the transcription of Keap1, though not significantly. Otherwise, NC had no effect on Nrf2 in regard to acute CDPP-induced nephrotoxicity.

CONFLICTS OF INTEREST
All authors declare that they have no conflicts of interest.

REFERENCES
1. Yang Y, Liu H, Liu F, Dong Z. Mitochondrial dysregulation and protection in cisplatin nephrotoxicity. Arch Toxicol 2014;88:1249-56.
2. Walker RJ, Endre ZH. Cellular mechanism of drug nephrotoxicity. In: Alpern RJ, Moe OR, Caplan MJ, editors. Seldin and Giebisch’s the Kidney. 5th ed. Philadelphia, PA: Saunders Elsevier; 2013. p. 2889-932.
3. Karasawa T, Steyer PS. An integrated view of cisplatin-induced nephrotoxicity and ototoxicity. Toxicol Lett 2015;237:219-27.
4. Indhumathi P, Shanmuga PE. Incidence and management of treatment-related side effect for patients receiving platinum therapy in an outpatient oncology clinic. Asian J Pharm Clin Res 2017;10:117-20.
5. Liu M, Grigoryev DN, Crow MT, Haas M, Yamamoto M, Reddy SP, et al. Transcription factor nrf2 is protective during ischemic and nephrotoxic acute kidney injury in mice. Kidney Int 2009;76:277-85.
6. Ma Q. Role of nrf2 in oxidative stress and toxicity. Ann Rev Pharm Toxicol 2013;53:401-26.
7. Soetikno V, Sari FR, Lakshmanan AP, Arumugam S, Harima M, Suzuki K, et al. Currin alleviates oxidative stress, inflammation, and renal fibrosis in remnant kidney through the nrf2-keap1 pathway. Mol Nutr Food Res 2013;57:1649-59.
8. Da’I M, Suhendi A, Meiyanto E, Jenie UA, Kawachi M. Apoptosis induction effect of curcumin and its analogs pentagamavunon-0 and pentagamavunon-1 on cancer cell lines. Asian J Pharma Clin Res 2017;10:373-6.
9. Shrishaill D, Handral HK, Ravichandra H, Tulisianand G, Shruthi SD. Turmeric: Nature’s precious medicine. Asian J Pharm Clin Res 2013;6:10-6.
10. Waly MI, Al Moundhri MS, Ali BH. Effect of curcumin on cisplatin- and oxaliplatin-induced oxidative stress in human embryonic kidney (HEK) 293 cells. Ren Fail 2011;33:518-23.
11. Kuhad A, Pilkhey S, Sharma S, Turkey N, Chopra K. Effect of curcumin on inflammation and oxidative stress in cisplatin-induced experimental nephrotoxicity. J Agric Food Chem 2007;55:10150-5.
12. Tapia E, Soto V, Ortiz-Vega KM, Carceles MT, Molina-Jijon E, Cristóbal-García M, et al. Currin alleviates oxidative stress, inflammation, and renal fibrosis in remnant kidney through the nrf2-keap1 pathway. Mol Nutr Food Res 2013;57:1649-59.
13. Balogun E, Hoque M, Gori P, Killeen E, Green CJ, Foresti R, et al. Curcumin activates the haem oxygenase-1 gene via regulation of nrf2 and the antioxidant-responsive element. Biochem J 2003;371:887-95.
14. Rahimi HR, Nedaemina R, Sepelhi Shamiloo A, Nikdoust S, Kazemi Oskee R. Novel delivery system for natural products: Nano-curcumin formulations. Avicenna J Phytopharm 2016;6:383-98.